Healthcare Cost Analysis, Bereavement and Frailty, and more
Read a healthcare cost analysis for patients taking ixekizumab compared to secukinumab or adalimumab, as well as about bereavement and frailty, and more.
Related Articles
Modafinils Versus Solriamfetol for Various Sleep Disorders | Docwire News
Most patients switching from modafinils to solriamfetol preferred it, citing better effects; others reverted due to side effects.
Pembrolizumab and Lenvatinib for Uterine Carcinosarcoma Treatment | Docwire News
The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment.
Genomic Profiling in Uterine Leiomyosarcoma | Docwire News
Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens.
Neoadjuvant Pepinemab Primes Tumor Immunity | Docwire News
This was an unexpected finding because mature TLS are typically rare in poorly immunogenic HPV-negative HNSCC.
Comparative Efficacy of Therapies for Locally Advanced Cervical Cancer | Docwire News
The findings reaffirm concurrent chemoradiotherapy as a cornerstone of treatment.
Pap-ctDNA Yields High Sensitivity in Endometrial Cancer | Docwire News
Tumor mutations were even detected in early-stage disease.
Clinical Predictors of Early Cutaneous Melanoma Recurrence | Docwire News
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Organoids Offer Insight Into Melanoma Drug Resistance | Docwire News
Patient-derived cells have the potential to enhance drug screening tools and improve patient outcomes.
New Study Shows Who Benefits Most and When From Eczema Drug Lebrikizumab | Docwire News
Study finds early lebrikizumab response in AD linked to lower inflammation—may guide personalized treatment plans.
Upadacitinib Shows Promise for Hidradenitis Suppurativa | Docwire News
Treatment with the drug demonstrated lesion and pain control in moderate to severe disease.